Uswm Ct, Llc

This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…

This study tests a new treatment called ADP-A2M4CD8, made from a patient's own immune cells, for ovarian cancer that has returned. It is given alone or with another drug (nivolumab) to see if it can shrink tumors. About 66 people with a specific genetic marker (HLA-A*02 and MAGE-…

This study tests a new treatment using a patient's own immune cells that are genetically modified to better recognize and attack certain solid tumors. It is for people with advanced cancers like synovial sarcoma that have not responded to other treatments. The goal is to see if t…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This phase 2 trial tests a one-time infusion of a patient's own immune cells that have been genetically modified to recognize and attack cancer cells. It is for people with advanced synovial sarcoma or myxoid liposarcoma whose tumors have a specific marker (MAGE-A4) and who have …

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …